

Patient Information:

- **Name:** Margaret Isolde Channing (born 13.01.1967)
- **Patient ID:** SYN060

Primary Diagnosis: BRAF V600E NSCLC with pleural dissemination

Molecular Profile:

- **PD-L1 Status:** TPS 90%, CPS 96, IC 3+
- **Date of Diagnosis:** 14.04.2022
- **Driver Mutation:** BRAF V600E (confirmed by NGS and IHC)

Treatment Course:

- **First-Line Therapy:** Dabrafenib 150 mg BID + Trametinib 2 mg daily since 06.05.2022
- **Current Status:** Ongoing, PR

Clinical Course: Ms. Channing presented with pleuritic chest pain and dyspnea. CT revealed pleural-based masses and malignant effusion. Thoracoscopy with biopsy confirmed BRAF V600E adenocarcinoma.

Treatment with BRAF/MEK inhibitors was initiated. Side effects included Grade 2 fatigue and Grade 1 pyrexia. After 6 months, pleural thickening regressed by 45%. Effusion has not recurred since talc pleurodesis.

Comorbidities:

- Hypothyroidism
- Migraine

Plan:

- Continue dabrafenib + trametinib
- Periodic ECG for QT monitoring
- Consider ipilimumab + nivolumab or chemoimmunotherapy upon progression

Dr. Juan Jimenez
San Diego, 13.12.2022